“CRISPR” is the word in the headline that signals that the piece is going to be about gene editing. Doc Gumshoe did not want to put that word – actually, it’s not really a word, but an acronym – in the title of this piece because gene editing is a whole lot more than […]
Articles
[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]
Remember Ernie Tremblay’s pitch about a “tiny South Texas lab” that was about to cure every disease using its revolutionary CD19 Cancer Vaccine technology, and ignite a bidding war following its fantastical release of exciting information on June 23? Well, it’s back. Not the stock, that’s still languishing around where it was before Tremblay got […]
[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues and trends. He does not typically write about specific investment opportunities, but has agreed to our trading restrictions… as with all of our authors, […]
Ray Blanco is running another ad with a near-term deadline for big anticipated stock movements — last time around, it was the pitch about Energous (WATT) and his conviction that Apple CEO Tim Cook would say something exciting about wireless charging for iPhones at the WWDC this year (that was yesterday, and Cook did no […]
Ridiculously huge gains are nothing new in biotech — they may not come easy, but they are sorely tempting… and, unlike with most “boring” companies that have ongoing businesses and have to build and compound to create lasting wealth, they can create fantastical gains almost overnight on the strength of a breakthrough clinical trial result […]
Gumshoe BioDimSum II: Corralling the “A” Biotechs Plus a New Long Selection[Ed. Note: Dr. KSS writes for our Irregulars about medicine and biotech stocks. As always, he has agreed our trading restrictions, and his words and opinions are his own. You can find all of his previous articles here. And now, for some dim sum….] Greetings Irregulars, and welcome to Stock Gumshoe’s festive second BioDimSum shindig, a periodic round-up […]
[ed note: Michael Jorrin, who I like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who shares his thoughts with us from time to time, generally on non-financial topics in health and medicine (as today, though, he mentions a couple publicly traded companies). His words and opinions are his own.] The […]
I’ve got a few thoughts for you on some companies I follow and own, and a little follow-up on last week’s chatter about hedge funds, but first I thought you’d like a quick teaser solution for your Friday File fun… The pitch is for Stephen Petranek’s Breakthrough Technology Alert — there’s been some discussion recently […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
No comments.